MA40106A1 - Anticorps anti-il-25 et leurs utilisations - Google Patents
Anticorps anti-il-25 et leurs utilisationsInfo
- Publication number
- MA40106A1 MA40106A1 MA40106A MA40106A MA40106A1 MA 40106 A1 MA40106 A1 MA 40106A1 MA 40106 A MA40106 A MA 40106A MA 40106 A MA40106 A MA 40106A MA 40106 A1 MA40106 A1 MA 40106A1
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- human
- bind
- disease
- geap
- Prior art date
Links
- 101000853002 Homo sapiens Interleukin-25 Proteins 0.000 abstract 5
- 102000055377 human IL25 Human genes 0.000 abstract 3
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 abstract 2
- 102100036680 Interleukin-25 Human genes 0.000 abstract 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 abstract 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 abstract 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 abstract 1
- 206010009900 Colitis ulcerative Diseases 0.000 abstract 1
- 208000011231 Crohn disease Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 206010020751 Hypersensitivity Diseases 0.000 abstract 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 102000013691 Interleukin-17 Human genes 0.000 abstract 1
- 108050003558 Interleukin-17 Proteins 0.000 abstract 1
- 201000006704 Ulcerative Colitis Diseases 0.000 abstract 1
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000007815 allergy Effects 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 230000005754 cellular signaling Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Pulmonology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Cardiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Transplantation (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Orthopedic Medicine & Surgery (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462054167P | 2014-09-23 | 2014-09-23 | |
| PCT/US2015/051407 WO2016049000A2 (en) | 2014-09-23 | 2015-09-22 | Anti-il-25 antibodies and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA40106A1 true MA40106A1 (fr) | 2018-06-29 |
Family
ID=54207847
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40106A MA40106A1 (fr) | 2014-09-23 | 2015-09-22 | Anticorps anti-il-25 et leurs utilisations |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9840557B2 (OSRAM) |
| EP (1) | EP3197914B1 (OSRAM) |
| JP (2) | JP6694877B2 (OSRAM) |
| KR (1) | KR102576368B1 (OSRAM) |
| CN (1) | CN107207589B (OSRAM) |
| AU (1) | AU2015321517B2 (OSRAM) |
| CA (1) | CA2961517C (OSRAM) |
| CL (2) | CL2017000703A1 (OSRAM) |
| CO (1) | CO2017003072A2 (OSRAM) |
| EA (1) | EA036658B1 (OSRAM) |
| IL (1) | IL251001B (OSRAM) |
| MA (1) | MA40106A1 (OSRAM) |
| MX (1) | MX2017003841A (OSRAM) |
| MY (1) | MY185832A (OSRAM) |
| PH (1) | PH12017500403A1 (OSRAM) |
| SG (2) | SG10201913084PA (OSRAM) |
| WO (1) | WO2016049000A2 (OSRAM) |
| ZA (1) | ZA201701663B (OSRAM) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913084PA (en) | 2014-09-23 | 2020-03-30 | Regeneron Pharma | Anti-il-25 antibodies and uses thereof |
| KR20240052871A (ko) | 2016-04-27 | 2024-04-23 | 애브비 인코포레이티드 | 항-il-13 항체를 이용한 il-13 활성이 유해한 질환의 치료 방법 |
| US11285191B2 (en) | 2016-07-26 | 2022-03-29 | The Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Immunostimulatory compositions and uses therefor |
| CN107213463A (zh) * | 2017-05-24 | 2017-09-29 | 清华大学 | 白介素25在银屑病的发育中的作用 |
| DE102017215154A1 (de) | 2017-08-30 | 2019-02-28 | Markus Bläss | Zusammensetzung zur topischen Behandlung von nicht-Mikroorganismus-verursachten entzündlichen Haut- und Schleimhauterkrankungen |
| CN112638940B (zh) * | 2018-11-19 | 2022-09-30 | 苏州鑫康合生物医药科技有限公司 | 抗-il-25抗体及其用途 |
| BR112022012093A2 (pt) | 2019-12-20 | 2022-08-30 | Momenta Pharmaceuticals Inc | Anticorpos contra integrina alfa 11 beta 1 |
| KR20210095781A (ko) | 2020-01-24 | 2021-08-03 | 주식회사 에이프릴바이오 | 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물 |
| US11365239B2 (en) | 2020-03-20 | 2022-06-21 | Tsb Therapeutics (Beijing) Co., Ltd. | Anti-SARS-COV-2 antibodies and uses thereof |
| WO2022150660A1 (en) * | 2021-01-08 | 2022-07-14 | 10X Genomics, Inc. | Antigen-binding polypeptides specific for coronaviruses and uses thereof |
| WO2023060144A1 (en) * | 2021-10-05 | 2023-04-13 | Lanier Biotherapeutics | Monoclonal antibodies to il-25 and uses thereof |
| CN119183384A (zh) * | 2022-02-24 | 2024-12-24 | 中国抗体制药有限公司 | 针对警报素的双特异性结合蛋白及其用途 |
| KR20250162899A (ko) * | 2023-03-31 | 2025-11-19 | 노바록 바이오테라퓨틱스 리미티드 | 항-il-25 항체 및 이의 사용 방법 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8308236D0 (en) * | 1983-03-25 | 1983-05-05 | Celltech Ltd | Dna vectors |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE122004000008I1 (de) | 1991-06-14 | 2005-06-09 | Genentech Inc | Humanisierter Heregulin Antikörper. |
| US7060802B1 (en) * | 2000-09-18 | 2006-06-13 | The Trustees Of Columbia University In The City Of New York | Tumor-associated marker |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| NZ573557A (en) | 2006-06-02 | 2010-08-27 | Regeneron Pharma | High affinity antibodies to human il-6 receptor |
| GB0707505D0 (en) | 2007-04-18 | 2007-05-30 | Medical Res Council | Antibodies against il-25 |
| GB0817891D0 (en) | 2008-09-30 | 2008-11-05 | Medical Res Council | Antibodies against il-25 |
| HRP20180340T1 (hr) | 2010-03-30 | 2018-03-23 | Janssen Biotech, Inc. | Humanizirana il-25 protutijela |
| WO2012097126A2 (en) * | 2011-01-13 | 2012-07-19 | The University Of Maryland, Baltimore | Il-25 treatment of obesity and metabolic disorders |
| JP2015521591A (ja) * | 2012-06-12 | 2015-07-30 | オレガ・バイオテック | Ｉｌ−１７アイソフォームのアンタゴニストおよびその使用 |
| SG10201913084PA (en) | 2014-09-23 | 2020-03-30 | Regeneron Pharma | Anti-il-25 antibodies and uses thereof |
-
2015
- 2015-09-22 SG SG10201913084PA patent/SG10201913084PA/en unknown
- 2015-09-22 WO PCT/US2015/051407 patent/WO2016049000A2/en not_active Ceased
- 2015-09-22 CA CA2961517A patent/CA2961517C/en active Active
- 2015-09-22 MY MYPI2017700743A patent/MY185832A/en unknown
- 2015-09-22 JP JP2017515768A patent/JP6694877B2/ja active Active
- 2015-09-22 CN CN201580063385.9A patent/CN107207589B/zh active Active
- 2015-09-22 US US14/861,320 patent/US9840557B2/en active Active
- 2015-09-22 MX MX2017003841A patent/MX2017003841A/es unknown
- 2015-09-22 AU AU2015321517A patent/AU2015321517B2/en active Active
- 2015-09-22 MA MA40106A patent/MA40106A1/fr unknown
- 2015-09-22 EA EA201790441A patent/EA036658B1/ru unknown
- 2015-09-22 KR KR1020177009048A patent/KR102576368B1/ko active Active
- 2015-09-22 EP EP15771489.0A patent/EP3197914B1/en active Active
- 2015-09-22 SG SG11201701712WA patent/SG11201701712WA/en unknown
-
2017
- 2017-03-03 PH PH12017500403A patent/PH12017500403A1/en unknown
- 2017-03-07 IL IL251001A patent/IL251001B/en active IP Right Grant
- 2017-03-08 ZA ZA2017/01663A patent/ZA201701663B/en unknown
- 2017-03-23 CL CL2017000703A patent/CL2017000703A1/es unknown
- 2017-03-29 CO CONC2017/0003072A patent/CO2017003072A2/es unknown
- 2017-11-07 US US15/805,584 patent/US10640558B2/en active Active
-
2018
- 2018-12-14 CL CL2018003608A patent/CL2018003608A1/es unknown
-
2020
- 2020-01-10 JP JP2020002597A patent/JP6916319B2/ja active Active
- 2020-02-27 US US16/803,582 patent/US11542326B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40106A1 (fr) | Anticorps anti-il-25 et leurs utilisations | |
| MA40035A (fr) | Molécules d'anticorps de pd-l1 et leurs utilisations | |
| MA46619B1 (fr) | Anticorps anti-il-33 et leurs utilisations | |
| MX2023004306A (es) | Un antagonista de il-4r para usarse en prevenir o tratar la alergia. | |
| WO2018191548A3 (en) | Complement factor d antagonist antibodies and conjugates thereof | |
| MA42622B1 (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA45125B1 (fr) | Anticorps anti-alpha-synucléine et leurs utilisations | |
| MA38814B2 (fr) | Agoniste gitr et antagoniste pd-1 pour leurs utilisations dans le traitement de troubles proliferatifs | |
| CY1111577T1 (el) | Συνθεσεις και μεθοδοι για την αντιμετωπιση ινωτικων διαταραχων | |
| WO2018069500A3 (en) | Anti-lag-3 antibodies and compositions | |
| MA49726B1 (fr) | Formulation d'anticorps anti-cgrp | |
| JO3462B1 (ar) | أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها | |
| MA38406B1 (fr) | Virus de la maladie de newcastle et leurs utilisations | |
| MA40497A (fr) | Anticorps et récepteurs antigéniques chimériques spécifiques du cd19 | |
| MA39061A1 (fr) | Modulateurs d'aplnr et leurs utilisations | |
| ATE469658T1 (de) | Kombinationstherapien gegen multiple toll-like- rezeptoren und ihre verwendung | |
| WO2015027206A8 (en) | Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof | |
| WO2017015622A8 (en) | Gdf11 binding proteins and uses thereof | |
| MA38478A1 (fr) | Anticorps anti-pac1 humains | |
| MA39342B2 (fr) | Anticorps il -21 | |
| MA39359A1 (fr) | Composés d'isoindolinone utilisés comme modulateurs de gpr119 pour le traitement du diabète, de l'obésité et de troubles associés | |
| MX375222B (es) | Compuestos y su uso para reducir los niveles de ácido úrico | |
| HK1232145A1 (zh) | 雙功能化合物和用於降低尿酸水平的用途 | |
| WO2018094300A8 (en) | ANTI-GITR ANTIGEN BINDING PROTEINS AND METHODS OF USE | |
| WO2010019565A3 (en) | Anti-ephrin b2 antibodies and their use in treatment of disease |